Sugi Predict

Sugi Predict / Compounds / SCHEMBL19285679

SCHEMBL19285679

SCHEMBL19285679

O=C(O)c1c(F)ccc(OCc2ccccc2)c1F

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ PTGER1 P34995 3/20 0.52
▸ MRGPRX4 Q96LA9 6/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ KDM1A O60341 2/20 0.49
▸ FOLH1 Q04609 2/20 0.49
▸ S1PR5 Q9H228 1/20 0.45
▸ NR4A1 P22736 1/20 0.45
▸ NR4A2 P43354 1/20 0.45
▸ NR4A3 Q92570 1/20 0.45
▸ FABP4 P15090 1/20 0.45
▸ CTSV O60911 1/20 0.44
▸ CTSL P07711 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30719659 1.00 PTGER1 (0.52) PTGER1MRGPRX4NPC1KDM1AFOLH1
SCHEMBL19285699 0.88 KDM1A (0.50) PTGER1MRGPRX4NPC1KDM1AFOLH1
SCHEMBL28316118 0.88 KDM1A (0.50) PTGER1MRGPRX4NPC1KDM1AFOLH1
SCHEMBL31388811 0.85 NPC1 (0.51) PTGER1MRGPRX4NPC1KDM1AFOLH1
SCHEMBL1495302 0.85 MRGPRX4 (0.55) PTGER1MRGPRX4FOLH1
SCHEMBL1495326 0.85 MRGPRX4 (0.54) PTGER1MRGPRX4NPC1FOLH1
SCHEMBL28496127 0.85 FOLH1 (0.49) PTGER1MRGPRX4NPC1FOLH1NR4A1
SCHEMBL2897224 0.83 MRGPRX4 (0.62) PTGER1MRGPRX4NPC1KDM1AFOLH1
SCHEMBL14829578 0.81 PTGER1 (0.47) PTGER1MRGPRX4NPC1S1PR5
SCHEMBL9267862 0.80 MRGPRX4 (0.52) PTGER1MRGPRX4NPC1FOLH1S1PR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250257074-A1 SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES TAXIS PHARMACEUTICALS, INC. (US) 2025-08-14 — — US disclosed
US-20250214974-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) PSY THERAPEUTICS, INC. (US) 2025-07-03 — — US disclosed
US-12286421-B2 Inhibiting monoacylglycerol lipase (MAGL) PSY THERAPEUTICS, INC. (US) 2025-04-29 — — US disclosed
US-20250084065-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) PSY THERAPEUTICS, INC. (US) 2025-03-13 — — US disclosed
US-12173013-B2 Synthetic processes and synthetic intermediates TAXIS PHARMACEUTICALS, INC. (US) 2024-12-24 — — US disclosed
US-20240308985-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) PSY THERAPEUTICS, INC. (US) 2024-09-19 — — US disclosed
CN-118290412-A Glutamate dehydrogenase degradation agent and preparation method and application thereof 杭州汉菁生物科技有限公司 2024-07-05 — — CN disclosed
CN-117794526-A Compositions and methods for antioxidants and anti-inflammatory therapeutics 阿万蒂生物科学股份有限公司 2024-03-29 — — CN disclosed
CN-110891566-B Synthesis method and synthesis intermediate 塔克西斯医药股份有限公司 2023-12-19 — — CN disclosed
US-20230257397-A1 SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES TAXIS PHARMACEUTICALS, INC. (US) 2023-08-17 — — US disclosed
US-20200055870-A1 SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES TAXIS PHARMACEUTICALS, INC. (US) 2020-02-20 — — US disclosed
EP-3600298-A1 SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES Taxis Pharmaceuticals, Inc. (US) 2020-02-05 — — EP disclosed
CN-110078680-A Isoxazoline benzamide compound and its preparation method and application 山东大学 2019-08-02 — — CN disclosed
US-20190048024-A1 SYNTHETIC PROCESSES AND INTERMEDIATES TAXIS PHARMACEUTICALS, INC. (US) 2019-02-14 — — US disclosed
US-20190048024-A1 SYNTHETIC PROCESSES AND INTERMEDIATES TAXIS PHARMACEUTICALS, INC. (US) 2019-02-14 — — US disclosed
CN-109195957-A Synthetic Methods and Intermediates 塔克西斯医药股份有限公司 2019-01-11 — — CN disclosed
EP-3419967-A1 SYNTHETIC PROCESSES AND INTERMEDIATES Taxis Pharmaceuticals, Inc. (US) 2019-01-02 — — EP disclosed
WO-2018183917-A1 SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES TAXIS PHARMACEUTICALS, INC. (US) 2018-10-04 — — WO disclosed
WO-2017147316-A1 SYNTHETIC PROCESSES AND INTERMEDIATES TAXIS PHARMACEUTICALS, INC. (US) 2017-08-31 — — WO disclosed
WO-2017147316-A1 SYNTHETIC PROCESSES AND INTERMEDIATES TAXIS PHARMACEUTICALS, INC. (US) 2017-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190048024-A1 SYNTHETIC PROCESSES AND INTERMEDIATES CYP11B1, CYP11B2, REN PTGER1 2351/4885MRGPRX4 1402/4885NPC1 1023/4885
US-20200055870-A1 SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES TXN, TBXAS1, TXK PTGER1 1939/4885MRGPRX4 1760/4885NPC1 4438/4885
US-20250214974-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) MGLL, PNLIP, LIPC PTGER1 4023/4885MRGPRX4 1186/4885NPC1 334/4885
US-20230257397-A1 SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES TXN, TBXAS1, TXK PTGER1 1939/4885MRGPRX4 1760/4885NPC1 4438/4885
US-20250257074-A1 SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES TXN, TBXAS1, TXK PTGER1 1939/4885MRGPRX4 1760/4885NPC1 4438/4885
US-20250084065-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) MGLL, PNLIP, LPL PTGER1 2238/4885MRGPRX4 917/4885NPC1 300/4885
US-12286421-B2 Inhibiting monoacylglycerol lipase (MAGL) MGLL, PNLIP, LIPC PTGER1 4023/4885MRGPRX4 1186/4885NPC1 334/4885
US-12173013-B2 Synthetic processes and synthetic intermediates TXN, TBXAS1, TXK PTGER1 1939/4885MRGPRX4 1760/4885NPC1 4438/4885
US-20240308985-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) MGLL, PNLIP, LIPC PTGER1 4023/4885MRGPRX4 1186/4885NPC1 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.